Shanghai, November 6, 2021/PRNewswire/ - Today, at the 4th China International Import Expo, Xinkelai (generic name: mepolizumab) became the world's first target approved for marketing The identity of human interleukin-5 (IL-5) antibody biologics was officially unveiled, hoping to provide new treatment options for Chinese patients and families affected by inflammatory diseases caused by eosinophilia .
The source of this page with content of products and services is from Internet,
which doesn't represent ECHEMI's opinion. If you have any queries, please write
to email@example.com. It will be replied within 5 days.
Moreover, if you find any instances of plagiarism from the page,
please send email to firstname.lastname@example.org with relevant evidence.